Influence of ganglioside combined with methylprednisolone sodium succinate on efficacy and neurological function in patients with acute myelitis

Yu-Fei Sun; Li-Li Liu; Sha-Sha Jiang; Xian-Juan Zhang; Feng-Jun Liu; Wan-Ming Zhang

doi:10.12998/wjcc.v11.i33.7972

Influence of ganglioside combined with methylprednisolone sodium succinate on efficacy and neurological function in patients with acute myelitis

World J Clin Cases. 2023 Nov 26;11(33):7972-7979. doi: 10.12998/wjcc.v11.i33.7972.

Authors

Yu-Fei Sun¹, Li-Li Liu², Sha-Sha Jiang², Xian-Juan Zhang³, Feng-Jun Liu⁴, Wan-Ming Zhang⁵

Affiliations

¹ Department of Special Medicine, Basic Medical College of Qingdao University, Qingdao 266071, Shandong Province, China.
² Department of Medical Microbiology, Basic Medical College of Qingdao University, Qingdao 266075, Shandong Province, China.
³ Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China.
⁴ Department of Special Medicine, School of Basic Medicine, Qingdao University, Qingdao 266000, Shandong Province, China.
⁵ Department of Special Medicine, Basic Medical College of Qingdao University, Qingdao 266071, Shandong Province, China. zhangwanming0532@126.com.

Abstract

Background: Acute myelitis (AM) can lead to sudden sensory, motor and autonomic nervous dysfunction, which negatively affects their daily activities and quality of life, so it is necessary to explore optimization from a therapeutic perspective to curb the progression of the disease.

Aim: To investigate the effect of ganglioside (GM) combined with methylprednisolone sodium succinate (MPSS) on the curative effect and neurological function of patients with AM.

Methods: First, we selected 108 AM patients visited between September 2019 and September 2022 and grouped them based on treatment modality, with 52 patients receiving gamma globulin (GG) + MPSS and 56 patients receiving GM + MPSS, assigned to the control group (Con) and observation group (Obs), respectively. The therapeutic effect, neurological function (sensory and motor function scores), adverse events (AEs), recovery (time to sphincter function recovery, time to limb muscle strength recovery above grade 2, and time to ambulation), inflammatory factors (IFs) [interleukin (IL)-6, C-reactive protein (CRP), and tumor necrosis factor (TNF)-α] and other data of the two groups were collected for evaluation and comparison.

Results: The Obs had: (1) A significantly higher response rate of treatment than the Con; (2) Higher scores of sensory and motor functions after treatment that were higher than the baseline (before treatment) and higher than the Con levels; (3) Lower incidence rates of skin rash, gastrointestinal discomfort, dyslipidemia, osteoporosis and other AEs; (4) Faster posttreatment recovery of sphincter function, limb muscle strength and ambulation; and (5) Markedly lower posttreatment IL-6, CRP and TNF-α levels than the baseline and the Con levels.

Conclusion: From the above, it can be seen that GM + MPSS is highly effective in treating AM, with a favorable safety profile comparable to that of GG + MPSS. It can significantly improve patients' neurological function, speed up their recovery and inhibit serum IFs.

Keywords: Acute myelitis; Ganglioside; Methylprednisolone sodium succinate; Neurological function; Therapeutic effect.